International Regulatory Landscape
Global standards, classifications, and harmonization challenges
Last updated: March 14, 2026
Regulatory Complexity
The regulatory status of medicinal leeches varies dramatically across jurisdictions. Understanding these differences is essential for researchers designing multinational studies, practitioners navigating scope-of-practice requirements, and organizations advocating for evidence-based policy.
Regulatory Comparison by Country
| Country | Classification | Regulatory Body | Status |
|---|---|---|---|
| USA | 510(k)-Cleared Medical Device | FDA (510(k), NRN) | 3 companies cleared; CBER transfer Dec 2024 |
| EU | Medical Device (MDR) | Notified Bodies (CE marking) | CE marked under EU 2017/745 |
| Russia | Biological Product | Ministry of Health | Most extensive clinical tradition; biofactories |
| Germany | Medical Device + Naturopathic | BfArM / Paul-Ehrlich-Institut | Heilpraktiker tradition; active research |
| India | Traditional Medicine (Ayurveda) | AYUSH Ministry | Jalaukavacharana — established Ayurvedic practice |
| South Korea | Research use | MFDS | Limited clinical use; research-focused |
| Japan | Research use | PMDA | Limited; some academic microsurgery programs |
United States — FDA Framework
510(k) Clearance
Medicinal leeches are cleared as 510(k) medical devices under the 510(k) pathway with product code NRN. Three companies hold active clearances. The cleared indication is for use as a “medicinal leech” for conditions where venous congestion may be a problem, such as in reconstructive microsurgery.
CBER Transfer (Dec 2024)
Regulatory oversight is transitioning from CDRH (Center for Devices and Radiological Health) to CBER (Center for Biologics Evaluation and Research), reflecting the biological nature of the product. This may affect future clearance pathways and post-market surveillance requirements.
European Union — MDR Framework
CE Marking under MDR (EU 2017/745)
The EU Medical Device Regulation classifies medicinal leeches as medical devices requiring CE marking through a Notified Body. The MDR transition from the previous Medical Device Directive (93/42/EEC) imposed stricter clinical evidence requirements. Manufacturers must demonstrate conformity with essential safety and performance requirements, including biocompatibility, sterility assurance, and clinical evaluation per MEDDEV guidance.
Russia — Extensive Clinical Tradition
Ministry of Health Protocols
Russia maintains the most extensive clinical tradition of hirudotherapy, with Ministry of Health treatment protocols, state biofactories for leech production, and specialized training programs. The Russian evidence base includes large observational cohorts across multiple specialties (cardiology, gynecology, neurology, dermatology). However, most studies predate modern CONSORT-compliant trial methodology and are published in Russian-language journals, limiting their accessibility to international systematic reviews.
WHO and Traditional Medicine Frameworks
WHO Traditional Medicine Strategy
The WHO Traditional Medicine Strategy 2014–2023 provides a framework for integrating traditional practices into national health systems. While there is no specific WHO regulation for leech therapy, the strategy encourages member states to develop regulatory frameworks that balance traditional knowledge with evidence-based evaluation. India's integration of Jalaukavacharana (leech therapy) within the AYUSH regulatory framework exemplifies this approach.
Harmonization Challenges
Classification Inconsistency
The fundamental question — is a medicinal leech a device, a medicine, or a traditional remedy? — receives different answers in different jurisdictions. This inconsistency complicates international clinical trials, import/export regulations, and mutual recognition of evidence.
Evidence Portability
Clinical evidence generated under one regulatory framework may not transfer directly to another. Russian observational data, while substantial, does not satisfy FDA requirements for additional indications. German RCTs provide the strongest internationally recognized evidence but were designed for publication rather than regulatory submission.
ASH Role in International Standards
ASH advocates for international harmonization of evidence standards for hirudotherapy. This includes promoting CONSORT-compliant trial design, supporting translation and systematic review of Russian-language literature, and engaging with the FDA CBER on evidence requirements for potential expanded indications. ASH recommends that all new clinical research follow internationally recognized guidelines (GRADE for evidence grading, CONSORT for trial reporting, PRISMA for systematic reviews) to maximize the global utility of generated evidence.